Surprisingly arsenous acid sodium salt, the compound of invention, has great therapeutic and safety advantages in comparison to arsenic trioxide. Arsenic trioxide AS_2O_3 has been shown to prolong the QT and QT interval corrected for rate (QT_C), which may predispose the patient to potentially fatal aytipical ventricular tachycardia and produce complete atrioventricular block.
Further more, adverse events occurring in 10% or more of patients treated with arsenic trioxide include fatigue, fever, oedema, chest pain, rigors, reactions at the injection site (ie pain, erythema, oedema), weakness, weight gain, nausea, anorexia, decreased appetite, diarrhoea or loose stools, vomiting, abdominal pain, dyspepsia, sore throat, constipation, hypokalemia, hypomagnesemia, increases in serum AST (SGOT) and/or ALT (SGPT), hyperkalemia, hypocalcemia, headache, insomnia, paresthesia, dizziness, tremor, cough, dyspnea, epistaxis, hypoxia, pleural effusion, postnasal drip, wheezing, decreased breath sounds, crepitations, rales, dermatitis, pruritus, ecchymosis, dry skin, erythema, sweating, tachycardia, ECG abnormalities, sinusitis, herpes simplex, upper respiratory infection, arthralgia, myalgia, bone pain, back pain, neck pain, limb pain, leukocytosis, anaemia, thrombocytopenia, neutopenia (may be febrile) , hypotension, hypertension, flushing, pallor, anxiety, depression, ocular irritation, blurred vision and vaginal haemorrhage.

Surprisingly none of these adverse events have been observed using the oral arsenous acid sodium salt, which is the compound of the present disclosure.
In another aspect, there is provided a use of sodium meta arsenite in the manufacture of a medicament for treatment of pain and/or inflammation associated with cancer.
In another aspect, there is provided a use of sodium meta arsenite in the manufacture of a medicament for treatment of pain and/or inflammation associated with cancer whereby the tumor size is not reduced.

Claims

1. Use of sodium meta arsenite in the manufacture of a medicament for treatment of pain and/or inflammation associated with cancer whereby the tumor size is not reduced.

2. The use according to claim 1 for the treatment of inflammation associated with cancer.

3. The use according to claim 1 for the treatment of pain associated with cancer.

4. The use according to claim 3 wherein the cancer is secondary bone cancer.

5. The use according to claim 1, wherein the cancer is prostate cancer.

6. The use according to claim 5, wherein the prostate cancer comprises bone metastasis or infiltration of non-prostate tissue.